Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : Gates Foundation invests $40 million in UK immunotherapy company

share with twitter share with LinkedIn share with facebook
09/18/2017 | 07:59am BST
FILE PHOTO: Melinda Gates and her husband attend a news conference in New York

LONDON (Reuters) - The Bill & Melinda Gates Foundation is to invest up to $40 million (29.41 million pounds) in privately held British biotech company Immunocore to support its development of immunotherapies for infectious diseases.

Oxford-based Immunocore has so far concentrated on developing its T-cell receptor medicines to fight cancer, where it has collaborations with Roche (>> Roche Holding Ltd.), GlaxoSmithKline (>> GlaxoSmithKline), AstraZeneca (>> AstraZeneca) and Eli Lilly (>> Eli Lilly and Company).

The tie-up with the Gates Foundation will extend the work into finding and developing new treatments for tuberculosis, HIV and other infectious diseases.

(Reporting by Ben Hirschler; Editing by Mark Potter)


share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
12:16aTo Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
DJ
10/23ASTRAZENECA : says its Oxford vaccine deal allows it to add up to 20% of manufac..
RE
10/23AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to..
RE
10/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/23Health Care Up After Final Presidential Debate -- Health Care Roundup
DJ
10/23ASTRAZENECA : Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S...
DJ
10/23ASTRAZENECA : Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resumin..
DJ
10/23ASTRAZENECA : Says FDA Authorises Restart Of COVID-19 Vaccine Trial in U.S.
RE
10/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials
Sales 2020 26 703 M - 20 481 M
Net income 2020 3 074 M - 2 358 M
Net Debt 2020 13 178 M - 10 107 M
P/E ratio 2020 47,1x
Yield 2020 2,72%
Capitalization 136 B 136 B 104 B
EV / Sales 2020 5,58x
EV / Sales 2021 4,86x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,27 $
Last Close Price 103,58 $
Spread / Highest target 50,1%
Spread / Average Target 14,2%
Spread / Lowest Target -36,3%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC4.42%135 994
JOHNSON & JOHNSON-0.43%382 391
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999